Akila S Weerasekera

Dr. Akila S Weerasekera

Harvard Medical School, Boston, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2020 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
ORO. Rapalino
O. Rapalino
Akila S WeerasekeraAkila S Weerasekera
Akila S Weerasekera
SMS.J. Moum
S.J. Moum
KEK. Eikermann-Haerter
K. Eikermann-Haerter
Brian L EdlowBrian L Edlow
Brian L Edlow
ERE.-M. Ratai
E.-M. Ratai
SUMMARY: Brain multivoxel MR spectroscopic imaging was performed in 3 consecutive patients with coronavirus disease 2019 (COVID-19). These included 1 patient with COVID-19-associated necrotizing leukoencephalopathy, another patient who had a recent pulseless electrical activity cardiac arrest with subtle white matter changes, and a patient without frank encephalopathy or a recent severe hypoxic episode. The MR spectroscopic imaging findings were compared with those of 2 patients with white matter pathology not related to Severe Acute Respiratory Syndrome coronavirus 2 infection and a healthy control subject. The NAA reduction, choline elevation, and glutamate/glutamine elevation found in the patient with COVID-19-associated necrotizing leukoencephalopathy and, to a lesser degree, the patient with COVID-19 postcardiac arrest, follow a similar pattern as seen with the patient with delayed posthypoxic leukoencephalopathy. Lactate elevation was most pronounced in the patient with COVID-19 necrotizing leukoencephalopathy.

12 October 2022 in Human Brain Mapping
Verified
Journal Article
Open access
Akila S WeerasekeraAkila S Weerasekera
Akila S Weerasekera
AIAdrian Ion‐Mărgineanu
Adrian Ion‐Mărgineanu
CGChristopher Green
Christopher Green
MMMaria Mody
Maria Mody
GNGarry P. Nolan
Garry P. Nolan
Whether brain matter volume is correlated with cognitive functioning and higher intelligence is controversial. We explored this relationship by analysis of data collected on 193 healthy young and older adults through the “Leipzig Study for Mind–Body–Emotion Interactions” (LEMON) study. Our analysis involved four cognitive measures: fluid intelligence, crystallized intelligence, cognitive flexibility, and working memory. Brain subregion volumes were determined by magnetic resonance imaging. We normalized each subregion volume to the estimated total intracranial volume and conducted training simulations to compare the predictive power of normalized volumes of large regions of the brain (i.e., gray matter, cortical white matter, and cerebrospinal fluid), normalized subcortical volumes, and combined normalized volumes of large brain regions and normalized subcortical volumes. Statistical tests showed significant differences in the performance accuracy and feature importance of the subregion volumes in predicting cognitive skills for young and older adults. Random forest feature selection analysis showed that cortical white matter was the key feature in predicting fluid intelligence in both young and older adults. In young adults, crystallized intelligence was best predicted by caudate nucleus, thalamus, pallidum, and nucleus accumbens volumes, whereas putamen, amygdala, nucleus accumbens, and hippocampus volumes were selected for older adults. Cognitive flexibility was best predicted by the caudate, nucleus accumbens, and hippocampus in young adults and caudate and amygdala in older adults. Finally, working memory was best predicted by the putamen, pallidum, and nucleus accumbens in the younger group, whereas amygdala and hippocampus volumes were predictive in the older group. Thus, machine learning predictive models demonstrated an age‐dependent association between subcortical volumes and cognitive measures. These approaches may be useful in predicting the likelihood of age‐related cognitive decline and in testing of approaches for targeted improvement of cognitive functioning in older adults.

7 October 2024 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
Akila S WeerasekeraAkila S Weerasekera
Akila S Weerasekera
DCDavid Richer Araujo Coelho
David Richer Araujo Coelho
EREva-Maria Ratai
Eva-Maria Ratai
KCKatherine Collins
Katherine Collins
Aura Maria Hurtado-PuertoAura Maria Hurtado-Puerto
Aura Maria Hurtado-Puerto
DIDan Vlad Iosifescu
Dan Vlad Iosifescu

7 March 2024 in Psychiatry Research: Neuroimaging
Verified
Journal Article
Open access
Akila S WeerasekeraAkila S Weerasekera
Akila S Weerasekera
AIAdrian Ion-Mărgineanu
Adrian Ion-Mărgineanu
GNGarry P. Nolan
Garry P. Nolan
MMMaria Mody
Maria Mody
Autism spectrum disorder (ASD) and schizophrenia (SZ) are neuropsychiatric disorders that overlap in symptoms associated with social-cognitive impairment. Alterations of the cingulate cortex, subcortical, medial-temporal, and orbitofrontal structures are frequently reported in both disorders. In this study, we examined white-matter connectivity between these structures in adults with ASD and SZ patients compared with their respective neurotypical controls and indirectly with each other, using probabilistic and local DTI tractography. This exploratory study utilized publicly available neuroimaging databases, of adults with ASD (ABIDE II; n = 28) and SZ (COBRE; n = 38), age-gender matched neurotypicals (NT) and associated phenotypic data. Tractography was performed using Freesurfer and MRtrix software, and diffusion metrics of white-matter tracts between cingulate-, orbitofrontal- cortices, subcortical structures, parahippocampal, entorhinal cortex were assessed. In ASD, atypical diffusivity parameters were found in the isthmus cingulate and parahippocampal connectivity to subcortical and rostral-anterior cingulate, which were also associated with IQ and social skills (SRS). In contrast, atypical diffusivity parameters were observed between the medial-orbitofrontal cortex and subcortical structures in SZ, and were associated with executive function (i.e., IQ, processing speed) and emotional regulation. Overall, the results suggest that defects in the isthmus cingulate, medial-orbitofrontal, and striato-limbic white matter connectivity may help unravel the neural underpinnings of executive and social-emotional dysfunction at the core of neuropsychiatric disorders.

27 June 2020 in Cerebral Cortex Communications
Verified
Journal Article
Open access
PDF file
Akila S WeerasekeraAkila S Weerasekera
Akila S Weerasekera
OLOron Levin
Oron Levin
ACAmanda Clauwaert
Amanda Clauwaert
KHKirstin-Friederike Heise
Kirstin-Friederike Heise
LHLize Hermans
Lize Hermans
SSStephan P Swinnen
Stephan P Swinnen
Suboptimal inhibitory control is a major factor contributing to motor/cognitive deficits in older age and pathology. Here, we provide novel insights into the neurochemical biomarkers of inhibitory control in healthy young and older adults and highlight putative neurometabolic correlates of deficient inhibitory functions in normal aging. Age-related alterations in levels of glutamate–glutamine complex (Glx), N-acetylaspartate (NAA), choline (Cho), and myo-inositol (mIns) were assessed in the right inferior frontal gyrus (RIFG), pre-supplementary motor area (preSMA), bilateral sensorimotor cortex (SM1), bilateral striatum (STR), and occipital cortex (OCC) with proton magnetic resonance spectroscopy (1H-MRS). Data were collected from 30 young (age range 18–34 years) and 29 older (age range 60–74 years) adults. Associations between age-related changes in the levels of these metabolites and performance measures or reactive/proactive inhibition were examined for each age group. Glx levels in the right striatum and preSMA were associated with more efficient proactive inhibition in young adults but were not predictive for reactive inhibition performance. Higher NAA/mIns ratios in the preSMA and RIFG and lower mIns levels in the OCC were associated with better deployment of proactive and reactive inhibition in older adults. Overall, these findings suggest that altered regional concentrations of NAA and mIns constitute potential biomarkers of suboptimal inhibitory control in aging.

13 January 2023 in Photonics
Verified
Journal Article
Open access
PDF file
DIDan Vlad Iosifescu
Dan Vlad Iosifescu
KCKatherine Collins
Katherine Collins
Aura Maria Hurtado-PuertoAura Maria Hurtado-Puerto
Aura Maria Hurtado-Puerto
MIMolly K. Irvin
Molly K. Irvin
JCJulie A. Clancy
Julie A. Clancy
PCPaolo Cassano
Paolo Cassano
We report on the rationale and design of an ongoing National Institute of Mental Health (NIMH) sponsored R61-R33 project in major depressive disorder (MDD). Current treatments for MDD have significant limitations in efficacy and side effect burden. There is a critical need for device-based treatments in MDD that are efficacious, well-tolerated, and easy to use. This project focuses on the adjunctive use of the transcranial photobiomodulation (tPBM) with near-infrared (NIR) light for the treatment of MDD. tPBM with NIR light penetrates robustly into the cerebral cortex, stimulating the mitochondrial respiratory chain, and also significantly increases cerebral blood flow (CBF). In the R61 phase, we will conduct target engagement studies to demonstrate dose-dependent effects of tPBM on the prefrontal cortex (PFC) CBF, using the increase in fMRI blood-oxygenation-level-dependent (BOLD) signal levels as our Go/No-go target engagement biomarker. In the R33 phase, we will conduct a randomized clinical trial of tPBM vs. sham in MDD to establish the target engagement and evaluate the association between changes in the biomarker (BOLD signal) and changes in clinical symptoms, while also collecting important information on antidepressant effects, safety, and tolerability. The study will be done in parallel at New York University/the Nathan Kline Institute (NYU/NKI) and at Massachusetts General Hospital (MGH). The importance of this study is threefold: 1. it targets MDD, a leading cause of disability worldwide, which lacks adequate treatments; 2. it evaluates tPBM, which has a well-established safety profile and has the potential to be safe in at-home administration; and 3. it uses fMRI BOLD changes as a target engagement biomarker. If effects are confirmed, the present study will both support short-term clinical development of an easy to scale device for the treatment of MDD, while also validating a biomarker for the development of future, novel modulation strategies.